Tests a sleep aid, suvorexant, for Alzheimer's risk in older adults
Tests whether the sleep drug suvorexant can slow amyloid buildup in older adults.
Key facts
- Who runs it
- University of Minnesota
- Where
- St Louis, United StatesSee the site
- Trial code
- Registry title
- Sleep Trial to Prevent Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 25 May 2022
- Expected to end
- May 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Suvorexant 20 mg
- Placebo
- Record updated
- 13 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 65 or older with no signs of dementia. It tests whether the sleep aid suvorexant slows amyloid-β build-up in the brain.
- Age
- 65 years or older
- Sex
- Men and women
- Disease stage
- Global Clinical Dementia Rating (CDR) of 0
- Earlier treatment
- Cannot have been in another trial with a study drug or device in the 30 days before joining
- Biomarker or test result
- Plasma A-beta and tau test with a plasma p-tau 217% above 1.19 (a result of 1.19 or lower excludes)
Main reasons for not taking part
- Restless legs syndrome, narcolepsy, other disorders of excessive sleepiness, or parasomnia
- Untreated sleep apnea (AHI 15 or higher on a home sleep test) or not using PAP as directed
- Stroke, chronic kidney disease, liver problems or HIV/AIDS
- Substance or alcohol abuse in the last 6 months, or regular drinking close to bedtime
- Currently pregnant or breast-feeding
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Male or female
- Any race or ethnicity
- Participants must be age ≥65 years and able to sign informed consent
- Global Clinical Dementia Rating (CDR) 0
- Willing and able to undergo study procedures
Who cannot take part
- Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment
- Must not participate in another drug or device study prior to the end of this study participation
- -• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery)
- History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
- Stroke
- HIV/AIDS
- History of substance abuse or alcohol abuse in the proceeding 6 months
- History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate
- Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:; Cardiovascular disease requiring medication except for controlled hypertension; Pulmonary disease; Type I diabetes; Neurologic or psychiatric disorder requiring medication; Tobacco use; Use of sedating medications; Use of medications that interact with suvorexant (if cannot be discontinued); Abnormal safety labs
- History of current suicidal ideations
- Chronic kidney disease defined as patients with markers of kidney damage or eGFR of < 45 ml/min/1.73m2
- Hepatic impairment defined as AST and/or ALT > 2x upper limit of normal (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L)
- STOP-Bang score >6 for participants without PAP
- Untreated OSA with AHI ≥15 on home sleep test
- Treated sleep apnea with PAP non-compliance; PAP compliance is defined as >= 4 hours per night >70% of the nights
- Plasma A-beta and tau test with a plasma p-tau 217% ≤ 1.19
- Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded
- Currently pregnant or breast-feeding
- In the opinion of the PI, the participant should be excluded due to an abnormal physical examination
Where in United States
- Washington University School of MedicineSt Louis, United StatesContact: Cristina Toedebusch, BSTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
The 2 groups in the trial
- Poor sleep treatment groupTreatment being tested
60 participants will be randomized to take suvorexant 20mg daily at h.s. for 18-24 months
Treatment: Suvorexant 20 mg
- Poor sleep control gropPlacebo, for comparison
60 participants will be randomized to take placebo daily at h.s. for 18-24 months
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sleep Trial to Prevent Alzheimer's Disease
- Plain-language title
- Tests a sleep aid, suvorexant, for Alzheimer's risk in older adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.Molecular neurodegeneration, 2025
- Record updated
- 13 July 2026